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b Sidra Medical and Research Centre, Doha, QatarThe history of clinical oncology has witnessed several revolutionary More recently, in December 2014, another anti-PD-1, nivolumab,
therapeutic advances that have signiﬁcantly improved cancer care.
These have included the introduction of cisplatin in the 1970s for
testicular and ovarian cancers, the taxanes in the 1990s for breast and
other solid tumors, targeted therapy with anti-HER2 for breast cancer
and c-Kit inhibitors for chronic myeloid leukemia and other cancers at
the start of thismillennium. Each of these treatments has revolutionized
outcomes for patients with various types of cancer. Today, we are at the
start of a new era in cancer care— that of immunotherapy. The approval
of sipuleucel-T for the treatment of prostate cancer in 2010 and
ipilimumab (anti-CTLA-4) for advanced melanoma in 2011 was the
ﬁrst notable success in the immunotherapy of cancer. After almost
three years from the approval of the ﬁrst checkpoint inhibitor
(ipilimumab), the good news is not over. Quite the contrary, we are
only at the beginning and, notably, these advances do not relate just
to the treatment of melanoma. Immunotherapy has become the fourth
pillar of cancer treatment alongside surgery, radiotherapy and chemo-
therapy (including targeted therapy). This can be attributed primarily
to the impact that another group of checkpoint inhibitors, the anti-PD-
1/PD-L1 agents, is having on the treatment of various malignancies.
As with anti-CTLA-4, the anti-PD-1/PD-L1 story starts with melano-
ma. Data from a large phase I study with pembrolizumab (Robert et al.,
2014a,b) led to its approval by the US Food and Drug Administration
(FDA) in September 2014 for the treatment of patients with
unresectable or metastatic melanoma and disease progression follow-
ing ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
This study of 411 patients showed that pembrolizumab resulted in an
overall response rate (ORR) of 34%, a median progression-free survival
(PFS) of 5.5 months, and overall survival (OS) rates of 69% at one year
and 62% at 18 months. Moreover, a randomized phase II trial with
pembrolizumab at two different dosages (2 mg/kg or 10 mg/kg every
three weeks) in advancedmelanoma refractory to previous ipilimumab
therapy showed that both doses improved PFS compared with investi-
gator choice chemotherapy (Ribas et al., 2014). In fact, the 6-month
PFS was 34% with pembrolizumab 2 mg/kg, 38% with pembrolizumab
10 mg/kg and 16% with chemotherapy, while the 9-month PFS was
24%, 29% and 8% respectively. The ORR in the three groups was 21%,
25% and 4%, respectively.⁎ Corresponding author.
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the same indication as pembrolizumab. Data from a large phase I trial
with nivolumab showed an ORR of 32% and 1, 2, 3, and 4-year OS
rates of 63%, 48%, 42%, and 32%, respectively. In addition, data from a
phase III study in patients withmetastatic melanomapreviously treated
with ipilimumab reported that nivolumab had an ORR of 32% compared
with 11% with the chemotherapy control arm (D'Angelo et al., 2014).
Nivolumabwas also compared to chemotherapy in another randomized
phase III trial in which untreated patients with advanced BRAF wild-
type melanoma received either nivolumab or dacarbazine. The ORR
was 40.0% in the nivolumab group versus 13.9% in the dacarbazine
group. At 1 year, the OS was 73.0% in the nivolumab group compared
with 42.1% in the dacarbazine group. Median PFS was 5.1 months in
the nivolumab group versus 2.2 months in the dacarbazine group
(Robert et al., 2014a,b).
Considering historical data with a typical median OS of 6.2 months
and 1-year OS rate of 25.5% and 1 and 2-year OS rates of 45% and 24%
obtained with ipilimumab therapy in the treatment of advanced mela-
noma, the results achieved with anti-PD-1 therapy represent a terriﬁc
improvement in clinical beneﬁt for these patients. Moreover, these
data obtained in melanoma patients are just the start.
OS data from a phase I study of nivolumab in solid tumors were
particularly encouraging, even in patients with non-small-cell lung
cancer (NSCLC), with a median OS of 9.6 months, 1-year OS of 42%
and 2-year OS of 24%. Moreover, in a phase II study in patients with ad-
vanced, refractory NSCLC, nivolumabwas associatedwith anORR of 15%
and a median OS of 8.2 months (Ramalingam et al., 2014). Historically,
these patients have ORRs of between 2 and 8% and a median OS of
about 5 months. The estimated 1-year survival rate was 41%, which
also compares favorably with historical data for patients with third-
line squamous cell NSCLC of 1-year OS rates of 5.5–18%. Pembrolizumab
has also shown interesting results in NSCLC. In the NSCLC expansion
cohort of a phase I trial, pembrolizumab treatment resulted in an ORR
of 21%. The median PFS in treatment-naïve patients was 27 weeks and
6-months OS was 86%, while in pretreated patients median PFS was
10 weeks and 6-months OS was 59% (Garon et al., 2014).
Interesting preliminary results have also been reported for urothelial
bladder cancer (UBC) and triple negative breast cancer (TNBC). In pa-
tients with platinum-pretreated, metastatic UBC, the ORR obtained
with an anti-PD-L1 antibody (MPDLA3280) was between 11% and
43%, depending on the level of PD-L1 (Powles et al., 2014). In patientsthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ORR of 18.5% with a durable response (median response duration was
not reached) (Nanda et al., 2014).
Anti-PD-1 therapy has also achieved interesting results in patients
with hematological malignancies. In a small phase I study that enrolled
23 patients with relapsed or refractory Hodgkin's lymphoma that had
already been heavily treated, nivolumab resulted in a clinical beneﬁt
in all patients; theORRwas87% (20/23),with 17%having a complete re-
sponse and 70% a partial response. The remaining three patients (13%)
all had stable disease (Ansell et al., 2014). PFS at 6 months was 86%. In
another phase Ib study, pembrolizumab also demonstrated promising
antitumor activity in patients with heavily pretreated Hodgkin's lym-
phoma, with a 21% complete remission rate and an ORR of 65% (Craig
et al., 2014).
What canwe expect during 2015?New data in other types of cancer
are surely expected. Studieswith anti-PD-1/PD-L1 are ongoing in gastric
cancer, small-cell lung cancer, glioblastoma, colorectal cancer, Merkel
cell carcinoma and others. There are also likely to be more data
concerning the role of PD-L1 as a predictive marker, even though data
from phase III studies in melanoma seem to refute such a role. We will
also see more important news on the potential of anti-PD-1/PD-L1s in
combination with other approaches, including other immunotherapies
(e.g. checkpoint inhibitors), radiotherapy, chemotherapy and targeted
agents. We are observing the beginning of another new era in the
ﬁght against cancer: that of anti-PD-1/PD-L1 therapy.Conﬂicts of Interest
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